Cargando...
Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy
BACKGROUND: IL-33, found in high levels in participants with allergic disorders, is thought to mediate allergic reactions. Etokimab, an anti–IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies. METHODS: In this 6-week pl...
Gardado en:
| Publicado en: | JCI Insight |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society for Clinical Investigation
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6948865/ https://ncbi.nlm.nih.gov/pubmed/31723064 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.131347 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|